JP2024502479A5 - - Google Patents

Info

Publication number
JP2024502479A5
JP2024502479A5 JP2023541867A JP2023541867A JP2024502479A5 JP 2024502479 A5 JP2024502479 A5 JP 2024502479A5 JP 2023541867 A JP2023541867 A JP 2023541867A JP 2023541867 A JP2023541867 A JP 2023541867A JP 2024502479 A5 JP2024502479 A5 JP 2024502479A5
Authority
JP
Japan
Prior art keywords
polynucleotide according
variant
functional fragment
polynucleotide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502479A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/011878 external-priority patent/WO2022150732A2/en
Publication of JP2024502479A publication Critical patent/JP2024502479A/ja
Publication of JP2024502479A5 publication Critical patent/JP2024502479A5/ja
Pending legal-status Critical Current

Links

JP2023541867A 2021-01-11 2022-01-10 キメラ受容体療法 Pending JP2024502479A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163136074P 2021-01-11 2021-01-11
US63/136,074 2021-01-11
US202163136611P 2021-01-12 2021-01-12
US63/136,611 2021-01-12
US202163263001P 2021-10-25 2021-10-25
US63/263,001 2021-10-25
US202163263508P 2021-11-03 2021-11-03
US63/263,508 2021-11-03
PCT/US2022/011878 WO2022150732A2 (en) 2021-01-11 2022-01-10 Chimeric receptor therapy

Publications (2)

Publication Number Publication Date
JP2024502479A JP2024502479A (ja) 2024-01-19
JP2024502479A5 true JP2024502479A5 (cg-RX-API-DMAC7.html) 2025-01-20

Family

ID=82322745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541867A Pending JP2024502479A (ja) 2021-01-11 2022-01-10 キメラ受容体療法

Country Status (9)

Country Link
US (1) US20220220187A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274898A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024502479A (cg-RX-API-DMAC7.html)
KR (1) KR20230143140A (cg-RX-API-DMAC7.html)
AU (1) AU2022205683A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204211A1 (cg-RX-API-DMAC7.html)
IL (1) IL304292A (cg-RX-API-DMAC7.html)
MX (1) MX2023008115A (cg-RX-API-DMAC7.html)
WO (1) WO2022150732A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102742741B1 (ko) * 2017-10-18 2024-12-16 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
GB202201927D0 (en) * 2022-02-14 2022-03-30 Kings College Artificial microrna construct
IL318039A (en) * 2022-07-10 2025-02-01 Precigen Inc Polycistronic microRNA constructs for immune checkpoint inhibition
EP4743578A2 (en) * 2023-07-10 2026-05-20 Precigen, Inc. THERAPY FOR ALPHA-1 ANTITRYPSIN DEFICIENCY
WO2025029865A1 (en) * 2023-07-31 2025-02-06 Precigen, Inc. Cd19-targeted car t cell therapy
WO2025101959A1 (en) * 2023-11-08 2025-05-15 Renbio, Inc. Plasmid dna constructs for peptide hormone expression
US12435338B2 (en) 2023-11-22 2025-10-07 Wyvern Pharmaceuticals Inc. Composition for regulating production of interfering ribonucleic acid
WO2025137580A1 (en) * 2023-12-22 2025-06-26 Antiger Therapeutics, Inc. Class ii hla with inter-chain disulfide bond

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
JP6772062B2 (ja) * 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. 癌の免疫療法
CA3012344A1 (en) * 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
EP3635132A4 (en) * 2017-06-07 2021-05-26 Intrexon Corporation EXPRESSION OF NOVEL CELL MARKERS
KR102742741B1 (ko) * 2017-10-18 2024-12-16 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
US11649455B2 (en) * 2018-03-30 2023-05-16 University Of Geneva Micro RNA expression constructs and uses thereof
CA3105816A1 (en) * 2018-07-10 2020-01-16 Precigen, Inc. Ror-1 specific chimeric antigen receptors and uses thereof
CN114127268A (zh) * 2019-05-02 2022-03-01 塞利亚德股份公司 具有多重化的抑制性rna的细胞

Similar Documents

Publication Publication Date Title
AU2019328290B2 (en) Multi-chain chimeric polypeptides and uses thereof
CN112300269B (zh) Kras突变特异性t细胞受体筛选及抗肿瘤用途
JP2019525914A5 (cg-RX-API-DMAC7.html)
JP2021177771A5 (cg-RX-API-DMAC7.html)
JP2021511041A5 (cg-RX-API-DMAC7.html)
JP2023505492A5 (cg-RX-API-DMAC7.html)
JP2016514457A5 (cg-RX-API-DMAC7.html)
JP2020500510A5 (cg-RX-API-DMAC7.html)
JP2019527055A5 (cg-RX-API-DMAC7.html)
JP2015212284A5 (cg-RX-API-DMAC7.html)
Lee et al. Fibronectin facilitates the invasion of Orientia tsutsugamushi into host cells through interaction with a 56-kDa type-specific antigen
JP2021524270A5 (cg-RX-API-DMAC7.html)
JP2019530441A5 (cg-RX-API-DMAC7.html)
JPH08510756A (ja) ストレス蛋白質とその使用
IL292650B1 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
JP2018524987A5 (cg-RX-API-DMAC7.html)
JP2014508748A5 (cg-RX-API-DMAC7.html)
JP2021524275A5 (cg-RX-API-DMAC7.html)
JP2020532285A5 (cg-RX-API-DMAC7.html)
CN114736291B (zh) 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
CN111542546A (zh) 抗lag-3 抗体及其用途
JP2020512284A5 (cg-RX-API-DMAC7.html)
JP2023554379A5 (cg-RX-API-DMAC7.html)
King et al. Achieving cross-reactivity with pan-ebolavirus antibodies
JP2005523681A5 (cg-RX-API-DMAC7.html)